IDEXX Raises FY25 Outlook After Strong Q2 Growth

IDEXX Laboratories reported second-quarter 2025 revenue of $1.11 billion, up 11% year-over-year, and GAAP EPS of $3.63, both exceeding analyst expectations. Last year, the company posted Q2 EPS of $2.44 and revenue of $1.003 billion. The strong performance was fueled by rapid adoption of new diagnostic products, robust international growth, and gains in the Companion Animal Group segment. As a result, IDEXX raised its full-year 2025 EPS guidance to $12.40–$12.76 and revenue outlook to $4.205–$4.280 billion. Shares of IDEXX have surged nearly 30% in 2025, significantly outperforming the broader market. Management credits these results to continued product innovation and strong customer loyalty among veterinarians.